Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

State of New Jersey Common Pension Fund D grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.6 ...

Analysts have recently evaluated Halozyme Therapeutics and provided 12-month price targets. The average target is $66.78, accompanied by a high estimate of $75.00 and a low estimate of $53.00. Holding ...

Benchmark reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a ...